Arginine recycling in endothelial cells is regulated BY HSP90 and the ubiquitin proteasome system
- Xiaomin Wu,
- Xutong Sun,
- ,
- Qing Lu,
- Manivannan Yegambaram,
- Yali Hou
- University of Arizona,
- ,
- Augusta University,
- University of California at San Francisco
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOpen access
Sustainable Development Goals
- SDG 3 Good Health and Well
Abstract
<p>Despite the saturating concentrations of intracellular L-arginine, nitric oxide (NO) production in endothelial cells (EC) can be stimulated by exogenous arginine. This phenomenon, termed the “arginine paradox” led to the discovery of an arginine recycling pathway in which L-citrulline is recycled to L-arginine by utilizing two important urea cycle enzymes argininosuccinate synthetase (ASS) and argininosuccinate lyase (ASL). Prior work has shown that ASL is present in a NO synthetic complex containing hsp90 and endothelial NO synthase (eNOS). However, it is unclear whether hsp90 forms functional complexes with ASS and ASL and if it is involved regulating their activity. Thus, elucidating the role of hsp90 in the arginine recycling pathway was the goal of this study. Our data indicate that both ASS and ASL are chaperoned by hsp90. Inhibiting hsp90 activity with geldanamycin (GA), decreased the activity of both ASS and ASL and decreased cellular L-arginine levels in bovine aortic endothelial cells (BAEC). hsp90 inhibition led to a time-dependent decrease in ASS and ASL protein, despite no changes in mRNA levels. We further linked this protein loss to a proteasome dependent degradation of ASS and ASL via the E3 ubiquitin ligase, C-terminus of Hsc70-interacting protein (CHIP) and the heat shock protein, hsp70. Transient over-expression of CHIP was sufficient to stimulate ASS and ASL degradation while the over-expression of CHIP mutant proteins identified both TPR- and U-box-domain as essential for ASS and ASL degradation. This study provides a novel insight into the molecular regulation L-arginine recycling in EC and implicates the proteasome pathway as a possible therapeutic target to stimulate NO signaling.</p>
Publication Information
Output type
Scholary Output:
Contribution to journal
Article
Research
Peer-reviewOriginal language
English (US)Pages from-to (Number of pages)
Pages 12-19 (8 pages)Journal (Volume, Issue Number)
Nitric Oxide - Biology and Chemistry (Volume 108)Publication milestones
- Published - 03/01/2021
Publication status
Published - 03/01/2021
ISSN
1089-8603Publication IDs
- Scopus: 85098640229
- PubMed: 33338599
- ORCID: /0000-0001-8200-108X/work/87167243
Publication metrics
Metrics
Fractional count
2
Fractional count
0.22
Fractional count
7
Fractional count
0.78
Fractional count
2
Fractional count
1
SciVal
Author count
9
SciVal
Paper percentile
80
PlumX, opens in new tab
Captures
7
Citation count
10
Funding Details
This research was supported in part by HL60190 (SMB) , HL137282 (SMB/JRF) , HL134610 (SMB/TW) , HL142212 (SMB) , HL146369 (SMB/JRF/TW) , HL061284 (JRF) , and the Interdisciplinary Training in Cardiovascular Research T32 HL00724 9 (to XW) all from the National Institutes of Health . The authors have no conflicts of interest to declare.
This research was supported in part by HL60190 (SMB), HL137282 (SMB/JRF), HL134610 (SMB/TW), HL142212 (SMB), HL146369 (SMB/JRF/TW), HL061284 (JRF), and the Interdisciplinary Training in Cardiovascular Research T32 HL007249 (to XW) all from the National Institutes of Health. The authors have no conflicts of interest to declare.
FundersFunding numbers
Interdisciplinary Training in Cardiovascular Research
T32 HL007249
SMB/TW/JRF
HL061284
SMB/TW
HL146369, HL142212
NIH
-NHLBI
P01HL134610
SMB
-JRF
-